Partners Onyx And Bayer Settle Next-Gen Nexavar Lawsuit, Enter New Deal

Onyx dropped its lawsuit against partner Bayer in exchange for an agreement that lets it share the financial rewards of the compound at the heart of the controvers, regorafenib, now in Phase III for oncology indications.